Robbins Geller Starts Investigation into Soleno Therapeutics Over Securities Violations

Investigation Overview

A recent alert has been issued by Robbins Geller Rudman & Dowd LLP, indicating that an investigation into Soleno Therapeutics, Inc. (NASDAQ: SLNO) has commenced. The focus of this investigation is to assess potential violations of U.S. federal securities laws. The inquiry seeks to determine whether Soleno or any of its senior executives may have made misleading statements or failed to disclose crucial information that could affect investor decisions.

The Company and Product

On March 26, 2025, Soleno Therapeutics made headlines when it announced that the U.S. FDA had granted approval for VYKAT XR, an extended-release tablet designed to treat hyperphagia in children aged four and older as well as adults with Prader-Willi syndrome. The launch of VYKAT XR was anticipated as a significant milestone for the company, aiming to address a critical need in the management of Prader-Willi syndrome, which is characterized by insatiable hunger and related health complications.

Key Revelation During Earnings Call

However, during a quarterly earnings call on November 4, 2025, Soleno disclosed some concerning information. It revealed that approximately 8% of patients discontinued the use of VYKAT XR due to adverse side effects.* Moreover, during the same earnings call, CEO Anish Bhatnagar acknowledged that the company's launch trajectory for VYKAT XR had been disrupted following a negative report issued by short sellers in mid-August. This disruption was marked by a significant decrease in the number of start forms submitted and an increase in discontinuations related to non-serious adverse events.

Following this announcement, Soleno’s share price plummeted by more than 26%, raising considerable concern among investors who believe they may have been misled regarding the drug's viability and safety profile. Such a sharp decline necessitates a thorough investigation into the circumstances surrounding these disclosures and statements made by Soleno officials.

Call to Action for Investors

Robbins Geller has opened its doors to investors who may possess information relevant to the investigation or those who feel they have incurred financial losses due to Soleno’s conduct. Individuals can reach out directly via the contact details provided by the firm. They emphasize that cooperation from the investor community could be vital for a comprehensive understanding of the situation.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is renowned as one of the leading law firms focused on representing investors in securities fraud and shareholder litigation. The firm has achieved significant milestones, being recognized for securing more monetary relief for investors than any other firm in recent years, amounting to recoveries exceeding $2.5 billion in 2024 alone. With a robust team of 200 lawyers based in 10 offices, Robbins Geller stands out in the realm of securities litigation, having obtained some of the largest recoveries in history.

For more information about the investigation and ways to participate, interested parties can visit their official site. The ongoing situation with Soleno Therapeutics serves as a reminder of the complexities involved in publicly traded biotech firms, particularly as they navigate the balance between innovation and investor transparency.

Conclusion

In conclusion, the investigation into Soleno Therapeutics is a developing story that highlights significant aspects of securities law and investor rights. Investors and potential witnesses are being encouraged to reach out, indicating a proactive approach from Robbins Geller to uncover the truth behind the alleged violations. As events unfold, it will be crucial for stakeholders to remain informed and engaged with the implications of this situation.